TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Discrimination of active SARS-CoV-2 infection using lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anxiety levels in preoperative area
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stent Thrombosis Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Generalised Anxiety Disorder 7-item (GAD-7) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Brachial Artery Flow-Mediated Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dysmenhorrea (VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial thickness (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myoma's diameter (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proinflammatory and Prothrombotic Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of remission of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness of intervention (depressive symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of intervention (exercise behaviour)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete recovery of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency and intensity of VCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on PR and RR intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate of BMS-247550
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Symptom Checklist Short Form (SCL-K11)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Therapeutical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False Negative Rate (FNR) for Sentinel Lymph Node Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of post-injection delirium/sedation syndrome (PDSS) events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of cases with detected cause of death and/or major pathological lesions
Endpoint domain: Mortality/survival
Primary endpoint: T-GAP score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Agitation measured by NeuroBehavior Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Agitation measured by Clinical Global Impression of Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Muscle mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glycated Haemoglobin A1c (HbA1c) in percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glycated Haemoglobin A1c (HbA1c) in mmol/mol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lymphocyte Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Cost Per Participant Per Month at Month 12
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Cost Per Participant Per Month at Month 60
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incremental Cost-effectiveness Ratio (ICER)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Free flap re-exploration rate
Endpoint domain: Adverse events/effects
Primary endpoint: bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Complete myocardial perfusion after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage change of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of Serum Adiponectin from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of hsCRP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Insulin resistance from baseline by Homeostatic Model Assessment (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintenance or improvement in Neurological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absence of any major device related adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline Intradialytic Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Feeling of Thirst at Three Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline Dry Mouth at Three Months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Patients Dying of Neurological Death
Endpoint domain: Mortality/survival
Primary endpoint: Bioavailability of lenvatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Insulin Resistance Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in bone quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Patients With Contrast-induced Nephropathy (CIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: State of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma pharmacokinetics (AUCss,τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma pharmacokinetics (Css,max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who live longer than 12 months
Endpoint domain: Mortality/survival
Primary endpoint: surgeons perception about ease of application of clips or endoloop
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time of application of endoloop and polymer clip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dental fear and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endometriosis-associated pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to effective bag-mask ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician's correct assessment of mannequin airway issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control rate of hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All Cause Mortality (ACM) at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Significant Disease-Related Complication (SDRC)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Worksites
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increase in levels of faecal bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of connectivity maps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activity of autonomic nervous activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PROMIS Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of complete dermal apposition at 2-weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rates of wound infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of wound dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of optimal cosmesis at 3-months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain related to cutaneous anesthesia method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the Edema Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Perceived Stress Scale (PSS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of acute graft versus host disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in seated systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pathological complete regression (PCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue perfusion at six hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Diastolic Ocular Perfusion Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco Quit Attempts
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-traumatic Checklist - Military version (PCL-M)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Elbow Flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: reduction in patient fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Hospital-based Delivery Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in frequency of opioid/alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in opioid/alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quality of life: World Health Organization Quality of Life (WHOQOL)-BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ordinal scale outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak blood glucose following test meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relapse-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with clinically important intracranial injury (CIII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Expanded Disability Status Scale (EDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sub-basal corneal nerve fibre density (NFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sub-basal corneal nerve branch density (NBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sub-basal corneal nerve fibre length (NFL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sub-basal corneal nerve fibre tortuosity (NFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Genotype at the rs174537 SNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asynchrony index of patient ventilator asynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of venous thromboembolic (VTE) and/or arterial thromboembolic (ATE) events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Patients in Remission at 1 Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Wrinkle Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients in sustained remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dementia-type changes in brain structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of REP 2055 treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Days Per Week of Cannabis Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Depression Symptoms at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in IGF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of any grade hematological toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Polymyalgia Rheumatica Activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in total anaerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Solicited Local and Systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Seroprotection in Hemagglutination Inhibition (HI) Antibody Titer (Egg-derived Antigen) of >=40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Fold Increase (GMFI) in HI Antibody Titer (Egg-derived Antigen) From Pre-vaccination to 21 Days After Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maintenance of serum testosterone at or below castration level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: visual quality perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of days for wound to heal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Braden scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total new lesion volume in protected brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oral and Intravenous Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hospital for Special Surgery (HSS) Knee Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ECG stress test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Forced Vital Capacity percent predicted (FVC %p)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of retained devices
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Pleural Concentration Versus Time Curve (AUC) of amoxicillin and clavulanic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month Local Control Rate
Endpoint domain: Mortality/survival
Primary endpoint: Duration of inpatient psychiatric treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Sensitivity and specificity of the clinical algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability scale of Kurtzke EDSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe acute adverse events following infusion of EAGD T-cells
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Treatment-emergent Adverse Events (AEs) Related to Recombinant Human Interleukin-15 (rhIL-15)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Treatment-emergent Adverse Events (AEs) Related to Obinutuzumab
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-rater reliability for the gait test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-rater reliability for the WBB test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of hand eczema assessed by the hand eczema severity index (HECSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-Related Quality of Life assessed by Skindex-29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Amount of corticosteroids prescribed within the last year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of moderate or severe acute exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cognitive abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-surgical fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Subjects Who Had New Sexual Relationships
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mini-mental state examination (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Montreal cognitive assessment (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence Rate of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Composite measure of success of bariatric surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure (systolic, diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in arterial blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cold pressor test reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atazanavir plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Methemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sweat Sodium Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evaluation of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Esophago-gastric junction distensibility index (EGJ-DI) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: fatty liver content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VLDL1 apolipoprotein B production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL apolipoprotein A1 production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Progesterone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Survival/all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of digital mammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Carotid-intima media thickness (CIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Video head impulse test (VHIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate of Organoid Culture and Drug Screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate of Obtaining circulating tumor DNA (ctDNA) quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to assess change in ctDNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Adverse Events Reported
Endpoint domain: Adverse events/effects
Primary endpoint: Coronary artery diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete Radiological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on Katz's Activities of Daily Living scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life (QoL) by 5 dimensions
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (QoL) by visual analog scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life